ImmunoGen to Present Preclinical Data Highlighting Potential of Combining Mirvetuximab Soravtansine with an Immune Checkpoint...
November 11 2016 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced new preclinical data that demonstrate the potential
for enhanced activity when combining mirvetuximab soravtansine with
immune checkpoint inhibition. These data will be presented at the
Society for Immunotherapy of Cancer’s (SITC) 31st Annual Meeting,
which is being held November 9-13 in National Harbor, Maryland.
Mirvetuximab soravtansine is a first-in-class folate receptor
alpha (FRα)-targeting ADC and is entering a Phase 3 trial, FORWARD
I, as a single agent treatment for platinum-resistant ovarian
cancer. Mirvetuximab is also being assessed in combination regimens
with Keytruda®, an immune checkpoint inhibitor, as well as Doxil®,
carboplatin and Avastin® for both platinum-resistant and
platinum-sensitive ovarian cancer in the Phase 1b/2 FORWARD II
trial. The Company expects initial data from FORWARD II in
mid-2017.
“We are committed to continuing to drive innovation in the
research and development of ADCs for the treatment of cancer. These
preclinical data reinforce the potential of combining mirvetuximab
soravtansine with an immune checkpoint inhibitor, which we are
evaluating as part of our FORWARD II trial,” said Richard Gregory,
Ph.D., executive vice president and chief scientific officer of
ImmunoGen. “More broadly, these data suggest that ADCs using
ImmunoGen’s maytansinoid technology may have an important role in
promoting anti-tumor immunity in conjunction with immuno-oncology
drugs.”
In a poster presentation, the Company will report in vitro data
showing that treatment of FRα-expressing tumor cells with
mirvetuximab soravtansine activates monocytes, a type of antigen
presenting cell (APC). Monocyte activation required both the
antibody component of mirvetuximab soravtansine, which interacts
with Fcγ receptors on APCs and its cancer-killing agent DM4, which
promotes immunogenic cell death of the tumor cells. Activation of
APCs in the presence of tumor neo antigen would trigger an
anti-tumor T cell response that could be enhanced by immune
checkpoint inhibition.
Poster PresentationTitle: “Treatment of Tumor Cells with
Mirvetuximab Soravtansine, a FRα-Targeting Antibody-Drug Conjugate
(ADC), Activates Monocytes Through Fc-FcγR Interaction and
Immunogenic Cell Death”
- Poster session #316: Saturday, November
12 at 11:45pm ET.
For additional information, visit the SITC Annual Meeting
website.
About Mirvetuximab SoravtansineMirvetuximab soravtansine
(IMGN853) is the first FRα-targeting ADC. It uses a FRα-binding
antibody to target the ADC specifically to FRα-expressing cancer
cells and a potent anti-tumor agent, DM4, to kill the targeted
cancer cells.
Mirvetuximab soravtansine is ImmunoGen’s lead program and is
entering Phase 3 testing in the FORWARD I trial as a single agent
for the treatment of platinum-resistant ovarian cancer. The
candidate is also being assessed in combination regimens for both
platinum-resistant and platinum-sensitive disease in Phase 1b/2
FORWARD II trial.
About ImmunoGenImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary ADC technology. ImmunoGen’s lead product
candidate, mirvetuximab soravtansine, is being advanced to a Phase
3 trial for FRα-positive platinum-resistant ovarian cancer, and is
in Phase 1b/2 testing in combination regimens for
earlier-stage disease. ImmunoGen’s ADC technology is used in
Roche's marketed product, Kadcyla®, in three other clinical-stage
ImmunoGen product candidates, and in programs in development by
partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and
Takeda. More information about the Company can be found at
www.immunogen.com.
Keytruda®, Doxil®, Avastin® and Kadcyla® are registered
trademarks of their respective owners.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including mirvetuximab soravtansine,
including risks related to preclinical and clinical studies, their
timings and results. A review of these risks can be found in
ImmunoGen’s Annual Report on Form 10-K for the fiscal year ended
June 30, 2016 and other reports filed with the Securities and
Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161111005057/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen,
Inc.Amy Reilly, 781-895-0138amy.reilly@immunogen.comorFTI
Consulting Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024